Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trialWorkforce reduced by approximately 60%; management and CEO salaries reducedPlan designed to substantially reduce
Enlivex is cutting costs and laying off workers to save money. They want to focus all their strength on testing one medicine for knee pain.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.